drugset / Trial / NCT01663766
Phase I Study of Milatuzumab for Graft Versus Host Disease
NaSingle-groupOpen-labelTreatment
Summary
This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.
Timeline
- Start
- 2013-12
- Primary completion
- 2015-03
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | milatuzumab | Monoclonal antibody | — | Intravenous |